thymalfasin comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-03-21. Numbers and descriptions here follow the published literature rather than marketing material.
Routine handling calls for storage of the lyophilized powder at refrigerated temperatures, away from light, in a sealed container. Working solutions are often prepared in sterile water or buffer and kept cold between uses. Repeated freeze-thaw cycles are generally avoided because they can promote aggregation and loss of material. Laboratories usually record lot number, reconstitution date, and storage conditions so that any change in behavior can be traced to a specific preparation.
Reverse-phase high-performance liquid chromatography is the standard technique for assessing purity and concentration, because the peptide's hydrophobicity allows clean separation from related impurities. Mass spectrometry confirms molecular identity and detects sequence errors or truncations. Amino acid analysis and peptide mapping supply additional structural confirmation when required. Chromatographic purity values reported on certificates of analysis describe the proportion of the main peak and do not by themselves establish biological activity.
Like most short peptides, thymosin alpha-1 is susceptible to hydrolysis under strongly acidic or basic conditions and to oxidation when exposed to air over long periods. The acetylated amino terminus blocks one common degradation route, which contributes to the molecule's relative robustness in solution. Lyophilized material generally retains potency for extended periods when kept cold and dry. Once reconstituted, aqueous solutions are less stable and are typically used within a defined window rather than held indefinitely at ambient temperature.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
| Property | Value | Notes |
|---|---|---|
| Primary structure | 28 amino acid residues | N-terminally acetylated |
| Net charge at neutral pH | Negative | Acidic peptide |
| Typical purity assay | Reverse-phase HPLC | UV detection near 214 nm |
| Identity confirmation | Mass spectrometry | Matches expected molecular mass |
| Reconstitution solvent | Sterile water or saline | Follow supplier instructions |
临床研究将Tα1用于慢性病毒感染、肿瘤辅助治疗和疫苗佐剂等场景。部分试验报告了免疫学指标改善，但临床终点获益在不同研究中并不一致。系统综述指出，研究间在人群、剂量和联合方案上差异较大，难以汇总结论。因此，Tα1的确切临床地位仍属开放问题，需要更多高质量随机对照试验来澄清。其机制研究也需从体外实验向体内模型推进。
胸腺素α1对免疫系统的影响涉及多种细胞类型。研究表明，它可促进未成熟T细胞向成熟T细胞分化，并增强T细胞对抗原刺激的增殖反应。树突状细胞在Tα1存在下表达更高水平的共刺激分子，从而更有效地呈递抗原。此外，自然杀伤细胞的活性也观察到上升。这些效应并非直接杀伤病原体，而是调节宿主免疫应答的强度与方向。
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Identity and purity are usually checked by reverse-phase high-performance liquid chromatography, which separates the intact chain from truncated products, together with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion and amino acid analysis add sequence-level evidence. Release testing also covers water content, residual solvents, and counter-ions, all of which influence measured mass and stability. Related-peptide limits are commonly expressed as a percentage of total peak area, with individual unspecified impurities held below a lower threshold.
The lyophilized peptide is a white to off-white powder that dissolves freely in water and in aqueous buffers near neutral pH. Because the molecule carries a net negative charge under physiological conditions, saline and phosphate solutions are the usual vehicles, while strongly acidic media are avoided. Stock solutions are commonly divided into small aliquots so that repeated freezing and thawing can be limited, since cycling may encourage aggregation. Solubility in organic solvents is poor and those solvents are seldom used as primary diluents.
Recommended storage for the dry powder is a freezer near minus twenty degrees Celsius, kept desiccated and away from light. Once dissolved, the peptide is less stable and is usually held at two to eight degrees Celsius for short intervals or frozen for longer storage. Stability studies focus on the acetylated terminus and the disulfide linkage because those features define the intact molecule. Common degradation routes include cysteine oxidation, deamidation of asparagine or glutamine side chains, and slow formation of higher-molecular-weight species.
=== Amino acids === Of the Free Amino Nitrogen (FAN) that make up YAN, the amino acids arginine, proline and glutamine are the most abundant followed by alanine, threonine, serine and aspartic acid in much smaller concentrations though trace amounts of most known amino acids can be found in grape must. Proline is usually the most concentrated and can represent up to 30% of the total amount of amino acids. The exact amount FAN will vary and can range 22 to 1242 mg of nitrogen/liter of YAN being derived from free amino acids.
Sephadex is a cross-linked dextran gel used for gel filtration. It was launched by Pharmacia in 1959, after development work by Jerker Porath and Per Flodin. The name is derived from separation Pharmacia dextran. It is normally manufactured in a bead form and most commonly used for gel filtration columns. By varying the degree of cross-linking, the fractionation properties of the gel can be altered. These highly specialized gel filtration and chromatographic media are composed of macroscopic beads synthetically derived from the polysaccharide dextran. The organic chains are cross-linked to give a three-dimensional network having functional ionic groups attached by ether linkages to glucose units of the polysaccharide chains. Available forms include anion and cation exchangers, as well as gel filtration resins, with varying degrees of porosity; bead sizes fall in discrete ranges between 20 and 300 μm. Sephadex is also used for ion-exchange chromatography. Sephadex is crosslinked with epichlorohydrin.
To better compete with more diversified manufacturers, in 1955 Whirlpool acquired Seeger Refrigerator Company and RCA's air conditioner and cooking range lines. The company changed its name to Whirlpool-Seeger Corporation and began using the RCA-Whirlpool brand name. Whirlpool acquired International Harvester Company's refrigeration plant in Evansville, Indiana, in 1955. In 1956, a 100-acre (0.40 km2) administrative center was opened in Benton Harbor, Michigan. In 1957, the RCA Whirlpool Miracle Kitchen was introduced with an estimated 15 million television viewers. The company changed its name back to Whirlpool Corporation and brought in Robert Elton Brooker as president. At the 1959 American National Exhibition at Sokolniki Park, Moscow, Brooker presided over the Whirlpool kitchen. The Whirlpool kitchen inspired the Kitchen Debate between then Vice President Richard Nixon and Soviet Premier Nikita Khrushchev.
In populations with a low risk for type 2 diabetes, in lean subjects and women with auto-antibodies, there is a higher rate of women developing type 1 diabetes (LADA). Children of women with GDM have an increased risk for childhood and adult obesity and an increased risk of glucose intolerance and type 2 diabetes later in life. This risk relates to increased maternal glucose values. It is currently unclear how much genetic susceptibility and environmental factors contribute to this risk, and whether treatment of GDM can influence this outcome. The relative benefits and harms of different oral anti-diabetic medications are not yet well understood as of 2017. There are scarce statistical data on the risk of other conditions in women with GDM; in the Jerusalem Perinatal study, 410 out of 37,962 women were reported to have GDM, and there was a tendency towards more breast and pancreatic cancer, but more research is needed to confirm this finding. Research is being conducted to develop a web-based clinical decision support system for GDM prediction using machine learning techniques. Results so far demonstrated great potential in clinical practicality for automatic GDM prognosis.
Hemangiopericytoma with t(7;12)(p22;q13)-translocations is a rare affliction, in which a translocational mutation causes the fusion of the ACTB gene over GLI1 in Chromosome 12. Juvenile onset dystonia is a rare degenerative disease that affects the central nervous system; in particular, it affects areas of the neocortex and thalamus, where rod-like eosinophilic inclusions are formed. The affected individuals represent a phenotype with deformities on the median line, sensory hearing loss and dystonia. It is caused by a point mutation in which the amino acid tryptophan replaces arginine in position 183. This alters actin's interaction with the ADF/cofilin system, which regulates the dynamics of nerve cell cytoskeleton formation. A dominant point mutation has also been discovered that causes neutrophil granulocyte dysfunction and recurring infections. It appears that the mutation modifies the domain responsible for binding between profilin and other regulatory proteins. Actin's affinity for profilin is greatly reduced in this allele. The ACTG1 locus codes for the cytosolic γ-actin protein that is responsible for the formation of cytoskeletal microfilaments. It contains six exons, giving rise to 22 different mRNAs, which produce four complete isoforms whose form of expression is probably dependent on the type of tissue they are found in. It also has two different DNA promoters.
Sources: en.wikipedia.org
== Methodology == Category 1: Stability (weighted 25% of total) Prevalence of summary offense Prevalence of violent crime Threat of terrorism Threat of war Threat of civil disorder Category 2: Healthcare (20%) Availability of private health care Quality of private healthcare Availability of publicly funded health care Quality of publicly funded health care Availability of over-the-counter drug World Bank's general health care indicators Category 3: Culture & Environment (25%) Humidity, temperature rating Discomfort of climate to travelers Transparency International's level of corruption Social or religious restrictions Level of censorship Sporting availability from 3 sport indicators Cultural availability from 4 cultural indicators Food and drink from 4 cultural indicators Consumer goods and services from product availability Category 4: Education (10%) Availability of private education Quality of private education World Bank's state school indicators Category 5: Infrastructure (20%) Street network quality Public transport quality International transportation service quality Availability of good quality housing Energy provision quality Water provision quality Telecommunications quality
== Mechanisms of pathogenicity == The mechanisms of P. syringae pathogenicity can be separated into several categories: ability to invade a plant, ability to overcome host resistance, biofilm formation, and production of proteins with ice-nucleating properties.
=== Access in the United States === Before the Drug Addiction Treatment Act of 2000 (DATA), physicians were not allowed to prescribe narcotics to treat opioid dependence. People with narcotic dependence had to go to registered clinics to receive treatment. With DATA, Suboxone was the first medication approved for office-based treatment for opioid dependence. Suboxone has thus become widely used as a replacement for methadone as it can be prescribed by doctors in their offices, while methadone can only be provided at specialized addiction centers, of which there are a limited number, often making access difficult. Integrating Medication-Assisted Treatment into outpatient primary care practices improves patient access to Suboxone. Some physicians are also leading a movement to begin prescribing it out of the emergency department (ED), as some small studies have shown ED-initiated Suboxone to be effective with people more likely to remain in addiction treatment compared to those either referred to addiction treatment programs or those receiving just a brief intervention in the department. Access to Suboxone can be limited due to varying prior authorization requirements across different insurers. Prior authorization is used by insurance companies to limit certain medications' use by requiring approval before the insurance company will pay for them. This can influence a person's financial access and adherence. Financial access is determined through prior authorization approval, which the prescriber must request before the person can start the medication.
The FDA approved pembrolizumab for adults with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy with or without cisplatin after surgery, and then as a single agent. It is the first approval for head and neck squamous cell carcinoma in six years and the first overall perioperative approval for locally advanced head and neck squamous cell carcinoma. In November 2025, the US FDA approved pembrolizumab or pembrolizumab and berahyaluronidase alfa with enfortumab vedotin as neoadjuvant treatment followed by adjuvant treatment after cystectomy for adults with muscle invasive bladder cancer who are ineligible for cisplatin.
Inca technology includes devices, technologies and construction methods used by the Inca people of western South America (between the 1100s and their conquest by Spain in the 1500s), including the methods Inca engineers used to construct the cities and road network of the Inca Empire.
Sources: en.wikipedia.org
Along with pancuronium bromide and potassium chloride, thiopental is used in 34 US states to execute prisoners by lethal injection. A large dose is given to ensure rapid loss of consciousness. Although death usually occurs within ten minutes of the beginning of the injection process, some have been known to take longer. In December 2009, Ohio became the first state in the US to use a single dose of sodium thiopental for an execution, following the failed use of the standard three-drug cocktail during a prior execution, due to inability to locate suitable veins. Kenneth Biros was executed using the single-drug method. Washington became the second state in the US to use the single-dose sodium thiopental injections for executions. In September 2010, the execution of Cal Coburn Brown was the first in the state to use a single-dose, single-drug injection. His death was pronounced approximately one and a half minutes after the intravenous administration of five grams of the drug. After its use for the execution of Jeffrey Landrigan in the US, the United Kingdom introduced a ban on the export of sodium thiopental in December 2010, after it was established that no European supplies to the US were being used for any other purpose. The restrictions were based on "the European Union Torture Regulation (including licensing of drugs used in execution by lethal injection)".
== Pathology == Increased adrenaline secretion is observed in pheochromocytoma, hypoglycemia, myocardial infarction, and to a lesser degree, in essential tremor (also known as benign, familial, or idiopathic tremor). A general increase in sympathetic neural activity is usually accompanied by increased adrenaline secretion, but there is selectivity during hypoxia and hypoglycemia, when the ratio of adrenaline to noradrenaline is considerably increased. Therefore, there must be some autonomy of the adrenal medulla from the rest of the sympathetic system. Myocardial infarction is associated with high levels of circulating adrenaline and noradrenaline, particularly in cardiogenic shock. Benign familial tremor (essential tremor) (BFT) is responsive to peripheral β adrenergic blockers, and β2-stimulation is known to cause tremor. Patients with BFT were found to have increased plasma adrenaline but not noradrenaline. Low or absent concentrations of adrenaline can be seen in autonomic neuropathy or following adrenalectomy. Failure of the adrenal cortex, as with Addison's disease, can suppress adrenaline secretion as the activity of the synthesizing enzyme, phenylethanolamine-N-methyltransferase, depends on the high concentration of cortisol that drains from the cortex to the medulla.
PLGA is typically synthesized by ring-opening polymerization of the cyclic dimers lactide and glycolide, a method widely used because it allows better control over molecular weight and copolymer composition than direct condensation methods. Other reports show direct polycondensation of lactic acid and glycolic acid as another method, but this approach gives lower molecular weight material and is less suitable for producing controlled, high-performance PLGA grades. Common catalysts include tin(II) 2-ethylhexanoate and related organometallic catalysts, which are widely used in melt polymerization because of their activity and practical availability.
=== Development of Captopril === In 1967, the company changed its goals with a new president of The Squibb Institute, Arnold D. Welch. Cardiovascular drugs became an area of concentration. Ondetti gained inspiration from his previous work on peptides. Peptides are vital in-vivo components, but peptides are cleaved by peptidases, decreasing their utility as drugs. By inhibiting these peptidases, one could increase activity of peptide drugs. Ondetti started work on the isolation of angiotensin-converting enzyme inhibitors. By 1973, work on ACE inhibitors stopped followed by dissolution of the peptide program. In 1974, Ondetti resumed unofficial work on ACE inhibitors with strong resolve, "We said this was the thing that we had to do". The first step in making Captopril was determining the characteristics of the enzyme, discovered by comparing it to another enzyme, Carboxypeptidase A. His group tried thousands of compounds from the Squibb library, but none yielded satisfying results. After reading literature involving the peptides by Byers and Wolfenden, Ondetti pointed out flaws in their logic. He argued that using a strong chemical binder to the zinc in the enzyme would increase activity. He settled on using a sulfhydryl group which binds strongly to zinc. Ondetti had discovered Captopril, an ACE inhibitor with much better activity than previous compounds. Ondetti published his primary paper on his synthesis in Science, 1977. The first human trials were done in Switzerland because European drug testing regulations were less strict.
Clorazepate, sold under the brand name Tranxene among others, is a benzodiazepine medication. It possesses anxiolytic, anticonvulsant, sedative, hypnotic, and skeletal muscle relaxant properties. Clorazepate is an unusually long-lasting benzodiazepine and serves as a prodrug for the equally long-lasting desmethyldiazepam, which is rapidly produced as an active metabolite. Desmethyldiazepam is responsible for most of the therapeutic effects of clorazepate. It was patented in 1965 and approved for medical use in 1967.
Sources: en.wikipedia.org
The lyophilized solid is normally held at 2 to 8 °C in a sealed, light-protected container. Dry storage limits both hydrolysis and microbial growth. Material kept this way remains stable for the shelf life stated by the supplier.
Reverse-phase HPLC separates the peptide from related impurities and yields a purity estimate. Mass spectrometry confirms the expected molecular mass and flags sequence errors. The two techniques are commonly reported together on a certificate of analysis.
Short exposure during handling is not considered a major problem for the dry powder. Prolonged storage at ambient temperature, especially of reconstituted solutions, raises the risk of degradation. Cold storage remains the standard practice for longer periods.
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.